Genetic susceptibility to melanoma is defined by the presence of germline mutations in high‐risk and high penetrance melanoma susceptibility genes, such as cyclin‐dependent kinase inhibitor 2A, present in 20%–45% of familial CM cases, and BRCA1‐associated protein‐1, found in up to 28% of families with CM and OM.1 Here, CDKN2A is linked to cutaneous mastocytosis.